mFOLFOX6
mFOLFOX6 is a pharmaceutical drug with 56 clinical trials. Currently 17 active trials ongoing. Historical success rate of 71.4%.
Success Metrics
Based on 15 completed trials
Phase Distribution
Phase Distribution
14
Early Stage
29
Mid Stage
13
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
60.0%
15 of 25 finished
40.0%
10 ended early
17
trials recruiting
56
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Total Neoadjuvant Therapy in Rectal Cancer
Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
Preoperative Sequential Short-course Radiation Therapy and FOLFOX for Locally Advanced Rectal Cancer
Clinical Trials (56)
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Total Neoadjuvant Therapy in Rectal Cancer
Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
Preoperative Sequential Short-course Radiation Therapy and FOLFOX for Locally Advanced Rectal Cancer
Neoadjuvant mFOLFOX6 Chemotherapy Combined With Anti-PD-1 Therapy in MSS/pMMR Locally Advanced Rectal Cancer (FIRM02 Study)
Trial of Nivolumab With FOLFOX After Chemoradiation in Rectal Cancer Patients
mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRC
A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors
Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418)
ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer
Induction Chemotherapy for Locally Advanced Esophageal Cancer
Neoadjuvant Treatment With mFOLFOXIRI Plus Cadonilimab (AK104) Versus mFOLFOX6 in Locally Advanced Colorectal Cancer
A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors
A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC
A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors
A Clinical Study to Evaluate the Efficacy and Safety of Envafolimab Combined With Cetuxima-βand mFOLFOX6 in Patients With MSS, RAS/BRAF Wild-Type Metastatic Colorectal Cancer (mCRC)
Pre-Operative Treatment in REseCTable COlon CanceR
MFOLFOXIRI Plus PD-1 Inhibitor Vs MFOLFOX6 As Neoadjuvant Therapy for Locally Advanced Colon Cancer
Chemotherapy and Pembrolizumab, Followed by Pembrolizumab and Olaparib As Firstline Therapy in Her-2 Negative Gastric/GEJ Adenocarcinoma
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 56